Arkolith/Insider Trading/TVTX/Form 4

Baynes Roy D.

DirectorTravere Therapeutics, Inc. (TVTX) · full profile →Form 4 · filed Apr 16, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$1.4M
Net Open-Market Flow
-$1.4M
Transactions
12
7 non-derivative · 5 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Apr 14, 2026Option exercise(M)8K$17.94$144K46K
Apr 14, 2026Option exercise(M)9K$15.43$139K55K
Apr 14, 2026Option exercise(M)5K$18.27$82K59K
Apr 14, 2026Option exercise(M)5K$21.38$96K64K
Apr 14, 2026Option exercise(M)7K$17.11$115K70K
Apr 14, 2026Sell(S)26K$41.07$1.1M44K
Apr 14, 2026Sell(S)7K$42.12$284K38K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Apr 14, 2026Option exercise(M)8K—$00
Apr 14, 2026Option exercise(M)9K—$00
Apr 14, 2026Option exercise(M)5K—$05K
Apr 14, 2026Option exercise(M)5K—$05K
Apr 14, 2026Option exercise(M)7K—$07K

Transaction Codes

M
Option exercise / conversion
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001680739-26-000005) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML